Partner Studies
MalariaGEN partner studies are the building blocks of our consortial projects and community projects. Each partner study is led by an independent investigator and has its own scientific objectives. MalariaGEN adds value to partner studies by providing access to genotyping and sequencing technologies, and by providing a framework for sharing and integrating data across different studies.
Below are some examples of our partner studies. New partner studies are continually joining, and please note that this is not a comprehensive list.
Burkina Faso
- Severe malaria in Ouagadougou (CP1)
- Immunogenetics in Ouagadougou (CP2)
- Genome variation & signatures of Plasmodium falciparum population structure
- Human genome diversity in malaria endemic areas (CP3)
Bangladesh
Cambodia
- Genomics of parasite clearance
- Studies of artemisinin resistance
- ARC3 study of artemisinin resistance
Cameroon
- Severe malaria in Buea (CP1)
- Obtaining informed consent for family trio studies in Cameroon
- Human genome diversity in malaria endemic areas (CP3)
Gambia
- Severe malaria in Banjul (CP1)
- Challenges of collecting cord blood control samples
- Genetic variation in P. falciparum
- Human genome diversity in malaria endemic areas (CP3)
Ghana
- Severe malaria in Navrongo (CP1)
- Severe malaria in Kumasi (CP1)
- Challenges in recruiting cases of severe malaria
- Engaging with local communities in Northern Ghana
- Malaria epidemiology in Northern Ghana
- Human genome diversity in malaria endemic areas (CP3)
Kenya
- Severe malaria in Kilifi (CP1)
- Immnogenetics in Kilifi (CP2)
- Genome-wide assoctiation study of antimalarial drug resistance
- Human genome diversity in malaria endemic areas (CP3)
Malawi
Mali
- Severe malaria in Bamako (CP1)
- Immunogenetics in Manterourou (CP2)
- Immunogenetics in Pogonon (CP2)
- Signatures of Plasmodium falciparum population structure
- Diversity and parasite structure of malaria parasites
Nigeria
- Severe malaria in Ibadan (CP1)
Papua New Guinea
- Severe malaria in Madang (CP1)
- Experiences of conducting health research in Papua New Guinea
- Plasmodium falciparum genome variation
- Human genome diversity in malaria endemic areas (CP3)
Senegal
- Immunogenetics in Dielmo and Ndiop (CP2)
- Improving informed consent and ethics review processes
- Genetic linkage studies of resistance to malaria (CP4)
Sri Lanka
Sudan
- Immunogentics in the Sudan (CP2)
- Human genome diversity in malaria endemic areas (CP3)
Tanzania
- Severe malaria in Moshi (CP1)
- Immunogenetics in Moshi (CP2)
- Immunogenetics in Muheza (CP2)
- Community involvement and joint ownership of health research in Tanzania
- Human genome diversity in malaria endemic areas (CP3)
- Diversity and parasite structure of malaria parasites
Thailand
- Genetic linkage studies of resistance to malaria (CP4)
- ARC3 study of artemisinin resistance
- Drug resistance on the Thai-Burmese border
- Studies of artemisinin resistance
UK
Vietnam
- Severe malaria in Ho Chi Minh City (CP1)
- P. falciparum diversity in Vietnam
- Human genome diversity in malaria endemic areas (CP3)